BK1284 Traditional Chinese Medicine
- 853.343
- 0.0000.00%
健倍苗苗：盈喜預告
現代中藥集團：2023年報
中國中藥：2023年年報
白雲山：2024年第一季度報告
福森藥業：年報2023
吉林長龍藥業：宣派及派付特別股息及暫停辦理股份過戶登記手續
中國智能健康：二零二三年報
神威藥業：年度報告 2023
同仁堂科技：年報2023
同仁堂國藥：2023年年報
白雲山：2023年年報
吉林長龍藥業：董事會會議通告及建議宣派及派付特別股息
BAIYUNSHAN PH: Date of Board Meeting
Accelerating the integration of obstetrics and medicine! How to deal with the “two ends” problem during the differentiation period of pharmaceutical innovation? Industry figures predict future internal volume reduction
① The 7th Pharmaceutical Innovation Ecology Conference (2024 Xipai Conference) with the theme of “Reconstructing R&D and Clinical Value Transformation Ecology through the Differentiation Period” opened in Zhangjiang, Shanghai. ② How to achieve original innovation with high quality and high value, and how to efficiently commercialize post-marketing products and achieve clinical value are the focus of this conference. ③ Many participants made a judgment that domestic pharmaceutical companies will reduce internal volume in the future.
Multiple arrows in unison! Pharmaceutical innovation support policies are coming
Recently, many places, including Beijing, Guangzhou, and Zhuhai, have successively issued relevant policies (draft for comments) to support the high-quality development of the biomedical industry or innovative pharmaceutical devices. The intensive introduction of support policies and the tight schedule have attracted great attention from the industry.
JILIN CHANGLONG: ANNUAL REPORT 2023
JILIN CHANGLONG: 2023 ANNUAL RESULTS ANNOUNCEMENT
FUSEN PHARM: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
SHINEWAY PHARM: 2023 ANNUAL RESULTS ANNOUNCEMENT AND DECLARATION OF 2024 FIRST INTERIM DIVIDEND
CHINAHEALTHWISE: ANNOUNCEMENT OF ANNUAL RESULTSFOR THE YEAR ENDED 31 DECEMBER 2023